Aptar Pharma Enhances Manufacturing Capacity in North America
Aptar Pharma Enhances Manufacturing Capacity in North America
Aptar Pharma, part of AptarGroup, Inc., a recognized leader in drug delivery and consumer product technologies, has proudly announced a significant expansion at its facility in Congers, New York. This enhancement is a direct response to the increasing demand for effective prescription and consumer healthcare drug delivery systems across North America.
Welcoming the Future
During a recent ceremonial event, Aptar’s President and CEO, Stephan Tanda, alongside the executive committee, highlighted the importance of this expansion. They were joined by Aptar employees, government officials, and valued customers who came together to celebrate the growth of this state-of-the-art manufacturing location.
Originally established in 2002, the Congers site has undergone a substantial transformation, now boasting an additional 28,500 square feet dedicated to warehousing and manufacturing. With a total footprint of 160,000 square feet, the facility currently employs approximately 350 staff members and operates 14 injection presses alongside 25 machines and eight ISO certified clean rooms.
Strategic Global Expansion
“This expansion marks a crucial step in our long-term global growth strategy, which also encompasses significant investments in injectables in France and new manufacturing facilities in Suzhou, China, and Mumbai, India,” Tanda remarked. This local expansion aligns perfectly with Aptar's commitment to a ‘local for local’ approach, designed to effectively cater to the rising needs of North American pharmaceutical clients.
The Congers site plays a vital role in the production of innovative drug delivery systems. Among its notable products are the proprietary Unidose (UDS) Nasal Spray Systems for the opioid reversal drug naloxone, including Narcan, and the recently FDA-approved neffy (epinephrine nasal spray), which is a groundbreaking needle-free treatment for emergency allergic reactions.
Innovative Product Development
“We take great pride in being the preferred partner for drug delivery solutions, turning concepts into viable market opportunities while expediting the product development process,” stated Gael Touya, President of Aptar Pharma. He added that the North American segment of Aptar has displayed robust growth recently, focusing on continuous innovation in nasal drug delivery, components for injectables, enhancing patient experience, and sustainable practices.
In addition to its range of nasal delivery products, the extended facility focuses on producing Aptar Pharma’s ETFE PremiumCoat film-coated stoppers for the injectables market. This involves on-site molding and trimming performed in a new ISO-7 cleanroom, with finishing and automated vision inspection processes continuing in an ISO-5 cleanroom.
About Aptar Pharma
Aptar Pharma operates as a subsidiary of AptarGroup, Inc., a premier global player in the realm of drug and consumer product delivery systems. The company serves diverse markets including pharmaceuticals, beauty, food and beverage, personal care, and home care products. With its extensive market expertise, innovative designs, scientific advancements, and engineering capabilities, Aptar provides solutions that significantly impact the lives of countless consumers around the world. Headquartered in Crystal Lake, Illinois, Aptar employs over 13,000 dedicated professionals across 20 countries.
Frequently Asked Questions
What recent changes have been made by Aptar Pharma?
Aptar Pharma has recently expanded its manufacturing capacity at its Congers, New York facility to meet the growing demand for drug delivery systems.
What types of products does Aptar Pharma produce?
Aptar Pharma produces a variety of drug delivery systems, including nasal spray systems, stoppers for injectables, and solutions for various medical conditions.
Where are Aptar Pharma's manufacturing facilities located?
Aptar Pharma operates globally, with significant manufacturing facilities in locations including the United States, France, Suzhou in China, and Mumbai in India.
How does Aptar Pharma ensure product quality?
The company employs ISO certified clean rooms and adheres to stringent production standards to guarantee the quality of its drug delivery systems.
What markets does Aptar Pharma cater to?
Aptar Pharma serves multiple markets including pharmaceuticals, beauty products, food and beverages, personal care, and home care industries.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Evolus Expands Stock Incentives to New Non-Executive Roles
- Legal Action Announced for Metagenomi Investors – Key Details
- Understanding Your Rights as an Allarity Therapeutics Investor
- Investors Urged to Explore Legal Action Against Flux Power
- Understanding the Class Action Against Metagenomi, Inc. MGX
- Metagenomi, Inc. Investors File Class Action Under SEC Laws
- Investigation Launched Into Acadia Healthcare Company: Insights
- Stellantis N.V. Investors Urged to Act Before Key Deadline
- China's Shift to Local AI Chips and Impacts on Nvidia
- Robbins LLP Urges Coinbase Global Investors to Act Now for Returns
Recent Articles
- Jeffs' Brands Expands Fort's Reach with solid European Sales Growth
- Asana Welcomes Sonalee Parekh as New CFO to Drive Growth
- Trinity Biotech Expands Maternal Health Solutions with Acquisition
- Primerica Appoints Robert H. Peterman Jr. as COO
- Understanding Nvidia's Recent Stock Surge and CEO Insights
- BlackSky Technology Inc. Public Offering Announcement Insights
- Elcora Update: Progress on Management Cease Trade Order
- Upcoming Third Quarter Results Announcement by Medpace Holdings
- ParaZero Advances with $187K Drone Safety Order for Production
- SMART Global Holdings Set to Host Fiscal 2024 Q4 Earnings Call
- Detailed Analysis of Recent Nasdaq Short Interest Trends
- Werner Enterprises Plans Third Quarter Earnings Call Soon
- KB Home Sees Growth in Q3 2024 Amid Economic Challenges
- Stitch Fix Reports Q4 and Full-Year 2024 Financial Highlights
- Virtus Total Return Fund Inc. Announces New Distribution Information
- Lyell Immunopharma's Innovative Approaches Unveiled at Event
- CIT Bank Platinum Savings: A Smart Savings Choice for 2024
- LifeMD, Inc. Approves Dividend for Preferred Stockholders
- Investigation into Rentokil Initial plc: What Investors Should Know
- Aviat Networks Under Scrutiny: Investigation Launched for Investors
- Join Phillips Edison & Company for Their Upcoming Earnings Call
- Fulcrum Therapeutics Under Scrutiny: Investor Alert Announced
- Matrix Service Company Enhances Sustainability Efforts for 2024
- Class Action Opportunity for Taro Pharmaceutical Investors
- Investigation Launched Into Flux Power Holdings for Accounting Errors
- AMMO, Inc. Welcomes New CFO Amid Investigative Changes
- Explore the Top High Yield Savings Options for Your Needs
- BNY Mellon High Yield Strategies Fund Announces Cash Dividend
- Understanding the Challenges Faced by Modern Parents Today
- Axos Financial, Inc. Set to Release Q1 Fiscal 2025 Earnings Results
- Explore the Top Online Savings Accounts for 2024 Choices
- Bobbie Grafeld Joins BILL as Chief People Officer to Drive Growth
- Marygold Companies Raises Funding to Advance Fintech Rollout
- Rithm Capital Corp. Launches Major Common Stock Offering
- Fraud Allegations Prompt Class Action Against Outset Medical, Inc.
- Exploring the Growth of Silicones Market Across Industries
- Cuyahoga Valley National Park Fundraiser Celebrates Achievements
- Understanding the Recent Developments Surrounding Caleres, Inc.
- TEPEZZA® Approval in Japan Marks a New Era for Thyroid Eye Disease Treatment
- GDT Strengthens Global Presence with Strategic Acquisition
- Lightwave Logic and Polariton Technology Unveil Groundbreaking Modulators
- Lifeway Foods Evaluates Acquisition Proposal from Danone
- Renibus Therapeutics to Engage with Investors at Key Conferences
- Market Trends Impact AMN Healthcare Stock Performance
- OIA Stock Reaches New Heights with 52-Week High Performance
- Guidewire Stock Reaches New Heights with All-Time High Price
- Top Tech Stocks to Watch After Interest Rate Adjustments
- Uncovering the Speed and Value of Metro by T-Mobile's Network
- Leadership Changes at Organic Potash Corporation Impact Future
- Exciting Flavor Release: Mel's Maple Matcha Hits Stores Soon